- Most cysts under the skin are biologically inert — epidermoid and pilar cysts together account for more than 70% of all cutaneous cysts in large pathology series, and the lifetime risk that any cyst becomes cancer is so low it is measured in single-digit case reports per decade
- A single keratin stain — K10 versus K17 — usually tells a pathologist exactly which kind of cyst it is — epidermoid (K10+ only), eruptive vellus hair (K17+ only), steatocystoma and pilar cysts (both)
- Multiple cysts in unusual places can be a clue to a heritable disease — multiple epidermoid cysts on the limbs in a young patient should trigger evaluation for Gardner syndrome (APC gene), and multiple pilar cysts trace to a two-hit mechanism in PLCD1
- Dermoid cysts should never be lanced — incision and drainage almost guarantees recurrence and can convert a one-operation problem into a lifelong scar; complete surgical excision with the cyst wall intact is the only correct operation
- One cyst variant carries real malignant potential — the proliferating trichilemmal tumor, a rapidly growing scalp lesion in older women, accounts for less than 0.1% of skin cancers but has a molecular fingerprint (15q gain, 6q/6p22.2 loss) distinct from squamous cell carcinoma
- One in five lesions clinically called a "cyst" turns out to be something else on histology — basal cell carcinoma accounts for nearly half of these missed cancers, which is why every excised cystic lesion must go to pathology
- The phrase "sebaceous cyst" is a misnomer — what most patients (and many doctors) call a "sebaceous cyst" is actually an epidermoid cyst, which contains keratin, not sebum, and has no sebaceous glands in the wall
Evidence Snapshot
- The big two: Epidermoid and pilar cysts together account for more than 70% of all cutaneous cysts in large pathology series (Kamyab et al., 2020; Al-Khateeb et al., 2009)
- Diagnostic discordance: 20% of clinical "cyst" diagnoses are wrong on histology, and basal cell carcinoma accounts for 48.9% of the missed cancers (Kamyab et al., 2020)
- K10/K17 immunohistochemistry decoder: Epidermoid cysts K10+ only; eruptive vellus hair cysts K17+ only; steatocystoma multiplex and pilar cysts express both (Tomková et al., 1997)
- Imaging discrimination: Dermoid cysts average −68 Hounsfield units (the density of fat) on CT; epidermoid cysts average +19 HU (the density of keratin) (Yun et al., 2024)
- MRI for midline lesions: Sensitivity 100%, specificity 95.7% for intracranial extension versus 72.7% and 96.5% for CT (Meira Pazelli et al., 2024)
- Surgical excision is curative: Mayo pediatric dermoid cyst series 1/49 recurrence; 234-patient scalp series 0 recurrences; periorbital series 2.6% recurrence (Pryor et al., 2005; Prior et al., 2018; Montolío-Marzo et al., 2020)
- Evidence base: 56 PubMed-indexed studies including landmark immunohistochemical, genetic, imaging, and surgical-outcomes papers, OpenEvidence Regular fact-checked
What exactly is a cyst, and why do they come in so many flavors?
When a patient comes to my office and points to a bump under the skin, the conversation almost always begins the same way: "Is this a cyst?" And the honest answer is — almost certainly, yes. But "cyst" is one of the most overworked words in clinical medicine. A cyst is simply a fluid-, semi-fluid-, or keratin-filled cavity lined by epithelium. The word tells you about the architecture of the lump. It tells you nothing about its biology, its genetic origin, or its clinical behavior.
That is the entire reason this article exists. The seven major types of cutaneous cyst arise from completely different parts of the skin — the epidermis, the hair follicle's outer root sheath, the pilosebaceous duct, embryonic fusion lines, even synovial-like tissue at sites of old injuries. Each is born from a different developmental story. Each has a different genetic anchor. Each behaves differently. And — most importantly for patients — each has a different correct treatment.
The job of a Mohs surgeon and dermatopathologist is to look at a bump under the skin and answer three questions, in order: What kind of cyst is this, biologically? Is it telling me anything about the patient's genes that I need to act on? What is the right operation — and is there any operation we must absolutely avoid?
Think of "cyst" the way you would think of the word "vehicle." A bicycle, a sedan, a semi-truck, and a fire engine are all vehicles. They all roll on wheels. But you would not handle them the same way, you would not park them the same way, and you certainly would not approach them with the same set of expectations. Cysts are the same. The architecture is shared. The biology is not. The job of the doctor is to figure out which kind of vehicle is parked under your skin.
What are the two cysts dermatologists see most often?
If I had to teach a medical student exactly one fact about cutaneous cysts, it would be this: the two cysts you will see most often in your career are epidermoid cysts and pilar cysts, and together they account for the great majority of cystic lesions in any large pathology series (Kamyab et al., 2020; Al-Khateeb et al., 2009). Everything else — every rare cyst, every syndromic cyst, every diagnostic curveball — is built on top of that foundation. Master these two first.
The epidermoid cyst — the workhorse of dermatology
The epidermoid cyst — sometimes still called the epidermal inclusion cyst or, incorrectly, the "sebaceous cyst" — is the workhorse cyst of dermatology. It presents as a firm, mobile, discrete nodule, most commonly on the face, neck, or trunk. The defining clinical clue is a small central punctum — a dot in the middle of the lump that represents the original follicular opening through which the keratin-producing epithelium became inverted into the dermis. Patients often say it feels like a "little BB" or a "pebble" under the skin.
Histologically, the cyst wall is a sheet of stratified squamous epithelium that mirrors normal epidermis — including a granular layer with keratohyalin granules. That epithelium produces compact, laminated keratin that fills the cyst cavity. The wall contains no sebaceous glands. (This is why "sebaceous cyst" is a misnomer that I would politely ask all of us to retire from clinical vocabulary — true sebaceous cysts, called steatocystomas, are an entirely different entity that we will get to shortly.) On immunohistochemistry, the lining expresses keratin 10 (K10) but not keratin 17 (K17) — a fact that becomes diagnostically important when the picture is less clear (Tomková et al., 1997; Pérez-Muñoz et al., 2019).
On high-resolution ultrasound, epidermoid cysts appear as well-circumscribed, hypoechoic, homogeneous nodules. On CT they have higher attenuation than dermoid cysts because keratin is denser than sebum — average radiodensity around +19 Hounsfield units for epidermoid versus −68 HU for dermoid (Whittle et al., 2023; Yun et al., 2024).
When multiple epidermoid cysts are a genetic signal
Most epidermoid cysts are sporadic and isolated. Almost all are biologically inert. But there is a single pattern that I want every clinician — and every patient — to recognize: multiple epidermoid cysts, particularly on the extremities or in atypical locations, especially in a young patient.
That presentation is the cutaneous fingerprint of Gardner syndrome — an autosomal dominant disorder caused by germline mutations in the APC gene, which also causes the colorectal polyposis and the bony osteomas that define the syndrome (Shen-Wagner et al., 2024; Achar et al., 2022). A patient with Gardner syndrome has a near-certain lifetime risk of colorectal cancer if untreated. The cysts are sometimes the very first sign — they can appear in childhood, decades before any polyp is detected on a colonoscopy. A dermatologist who recognizes the pattern and refers to gastroenterology and genetics can change the trajectory of a life.
The cutaneous cyst can predate the colon polyps of Gardner syndrome by decades. A pediatric dermatologist who recognizes a child with multiple epidermoid cysts in unusual locations — and refers for genetic testing of the APC gene — has the power to redirect that family's surveillance and, in many cases, prevent colorectal cancer entirely. This is one of the clearest examples in medicine of the skin telling you about the inside of the body.
The pilar (trichilemmal) cyst — the scalp specialist
The pilar cyst arises from the outer root sheath of the hair follicle, and that is the single most important fact about it. The outer root sheath is the part of the hair follicle that wraps around the developing hair shaft, and its keratinization is biologically different from that of the epidermis. That difference accounts for everything about the pilar cyst — its location, its texture, its histology, and its imaging characteristics.
Pilar cysts present as slow-growing, intradermal nodules, almost always on the scalp. They lack the central punctum of an epidermoid cyst because they do not communicate with a follicular opening. They feel firmer to the touch than epidermoid cysts. On the scalp, they sometimes occur in clusters, and patients can develop several over the course of a lifetime.
Histologically, pilar cysts are lined by stratified squamous epithelium that — in a key diagnostic detail — lacks a granular layer. Their keratinization happens by a process called "trichilemmal keratinization," in which the cells transition abruptly to dense, compact, eosinophilic keratin without forming keratohyalin granules. The cyst contents are correspondingly dense and homogeneous (Shen-Wagner et al., 2024; Pérez-Muñoz et al., 2019). On immunohistochemistry, pilar cysts express both K10 and K17 — a profile that distinguishes them from both epidermoid cysts (K10+ only) and eruptive vellus hair cysts (K17+ only) (Tomková et al., 1997). A nuance for pathologists: K10 staining in pilar cysts can be variable in intensity and is often concentrated at foci of terminal differentiation rather than uniformly distributed throughout the cyst wall (Broekaert et al., 1990; Ohnishi & Watanabe, 1999) — but the K10+/K17+ signature remains diagnostically reliable.
The PLCD1 two-hit story — why "dominant inheritance" is not the whole truth
A subset of patients develops multiple pilar cysts, often in family clusters spanning several generations. In 2019, two paired papers — an editorial by Shimomura, O'Shaughnessy, and Rajan and the underlying mechanistic study by Hörer and colleagues — identified variants in the PLCD1 gene (which encodes phospholipase C delta 1, a signaling enzyme that the outer root sheath needs to function normally) as the cause of familial pilar cyst disease (Shimomura et al., 2019; Hörer et al., 2019).
The mechanism is more interesting than the simple "dominant inheritance" headline would suggest. Hörer and colleagues showed that cyst formation requires both a germline predisposing variant in PLCD1 and a second somatic mutation on the same allele — what they call a monoallelic two-hit mechanism. Inheriting the germline variant alone is not enough; the somatic hit is what drives clonal expansion in an individual hair follicle. Clinically the inheritance pattern looks dominant because the somatic hits accumulate over a lifetime — but molecularly the logic is closer to a tumor-suppressor model. This distinction is useful in the genetic counseling conversation: family members carry a predisposition, not a guarantee.
The two cysts that account for the great majority of clinical practice — epidermoid and pilar — can usually be distinguished by feel and location alone (epidermoid: punctum + face/neck/trunk; pilar: no punctum + scalp). When they are syndromic or familial, the genetic signals come in pairs: multiple epidermoid cysts on the limbs → think Gardner syndrome (APC); multiple pilar cysts in a family → think PLCD1 two-hit mechanism. The skin sometimes asks for a referral to genetics.
When does a scalp cyst become something more dangerous?
Most discussions of cysts treat them as a uniformly benign group. I do not, because there is one entity inside the pilar cyst family that breaks the rule: the proliferating trichilemmal tumor (PTT). This tumor arises from the same outer root sheath epithelium that gives us pilar cysts, but instead of forming a quiescent, slow-growing cavity, the PTT shows aggressive epithelial proliferation, occasional cytologic atypia, and — rarely — malignant transformation with metastatic potential (Satyaprakash et al., 2007; Sethi & Singh, 2002; Lee et al., 2023; Juan David et al., 2023).
The classic clinical scenario is the one I want every primary care doctor and dermatologist to remember: a long-standing, slow-growing scalp lump in an older woman that has recently begun to grow rapidly, ulcerate, or change in feel. That rapid change is the signal. The lesion you have watched for years is, in a sense, no longer the lesion you have been watching.
The molecular fingerprint that separates PTT from squamous cell carcinoma
For many years, pathologists struggled to distinguish a proliferating trichilemmal tumor from a cutaneous squamous cell carcinoma — particularly when atypia was prominent and the keratinization was aggressive. In 2023, Fischer, Lindeman, Ligon, and Russell-Goldman published a chromosomal analysis showing that PTTs carry a recurrent and reproducible molecular signature: broad arm-level gain of chromosome 15q, with concurrent losses of 6q and 6p22.2 (Fischer et al., 2023). That signature is molecularly distinct from cutaneous squamous cell carcinoma, which is driven by mutations in TP53, CDKN2A, and NOTCH1. For a dermatopathologist looking through the microscope at a rapidly growing scalp lesion with atypical features, this is genuinely useful information — the molecular profile resolves cases that morphology alone cannot.
What to do when you suspect a PTT
The standard of care is wide local excision with clear histologic margins, and patients deserve long-term follow-up because both local recurrence and (rarely) metastatic spread have been documented. Adjuvant radiotherapy or chemotherapy may be considered for invasive or metastatic disease, though such cases are rare enough that there are no large randomized trials guiding therapy (Satyaprakash et al., 2007; Lee et al., 2023). PTT accounts for less than 0.1% of all skin cancers — but the absolute rarity is exactly why an experienced eye on the scalp matters.
If a scalp cyst you have lived with for years suddenly starts to grow, change in feel, become tender, or ulcerate — do not assume it is "just inflamed." A proliferating trichilemmal tumor mimics a benign pilar cyst until it doesn't. Get it evaluated, and if it is excised, insist on histopathologic examination. Every excised cyst should go to pathology — that is the single rule that protects patients from the rare bad actor hiding inside the routine bump.
What is steatocystoma multiplex, and why is it called the "keratin 17 disease"?
Steatocystoma multiplex is the cyst that taught dermatology how powerful a single defective structural protein can be. The condition presents during adolescence or early adulthood as multiple, soft, skin-colored to yellowish nodules on the chest, neck, upper arms, and legs. The cysts are filled with sebum rather than keratin, and the cyst wall contains sebaceous glands embedded within it — a histologic feature that is pathognomonic (Tomková et al., 1997; Georgakopoulos et al., 2018).
The condition is caused, in most familial cases, by mutations in the KRT17 gene, which encodes keratin 17 — a structural protein essential to the integrity of sebaceous glands, nails, and the hair follicle. When KRT17 is defective, the keratin filaments that scaffold these structures cannot assemble correctly, and cysts form along the pilosebaceous duct. This genetic defect is the same gene that is mutated in pachyonychia congenita, a much more severe disorder that includes painful palmoplantar keratoderma and severely thickened nails. Steatocystoma multiplex is, in some ways, the milder phenotypic cousin of pachyonychia congenita — they share a gene but not the full clinical picture.
The K10/K17 stain — the most underused tool in cyst pathology
This is where the immunohistochemistry I mentioned earlier becomes diagnostically decisive. Steatocystoma multiplex expresses both K10 and K17. Eruptive vellus hair cysts — a clinical mimic — express K17 only. Epidermoid cysts express K10 only. A pathologist who runs a single panel of K10 and K17 can confidently distinguish these three otherwise visually similar lesions (Tomková et al., 1997).
Treatment — why wall removal is the only durable strategy
Steatocystoma multiplex is chronic and relapsing — patients live with it for decades. The most effective management is procedural removal of the cyst wall, not just drainage. Simple aspiration of contents always fails because the wall regenerates the cyst.
The technique with the best published outcomes is a modified surgical approach: puncturing the cyst with a sharp-tipped cautery, evacuating the sebaceous contents, and then extracting the cyst wall through the small opening (Kaya et al., 2001). The series describing this technique reported excellent cosmetic outcomes and no recurrence at 14 months.
Carbon dioxide (CO₂) laser perforation and extirpation is increasingly favored for facial or cosmetically sensitive areas, with precise tissue ablation, minimal bleeding, rapid healing, and high patient satisfaction at low recurrence and scarring rates (Bakkour & Madan, 2014; Rossi et al., 2003). Oral isotretinoin offers limited and often temporary benefit (Georgakopoulos et al., 2018).
If you have steatocystoma multiplex, the most important thing your doctor can do for you is be honest about expectations. This is a chronic condition. Removing the cysts that bother you most makes sense — those individual cysts will not come back if the wall is removed. But new cysts will appear over time because the underlying genetic defect is still there. The goal is not eradication — the goal is keeping you comfortable, cosmetically acceptable, and confident that the lumps you can see are still benign.
Why is "never lance a dermoid cyst" the most important rule on this page?
Dermoid cysts are different from every other cyst on this list because they are not the product of trapped adult epithelium — they are the product of embryologic sequestration along fusion lines during fetal development (Bansal et al., 2022; Santos et al., 2020). When the bones of the face and skull are forming, small pockets of ectodermal tissue can become trapped at the lines where bones come together. Those trapped tissues mature in place, producing a cyst that contains mature skin and its adnexal structures — sebaceous glands, hair follicles, sometimes even respiratory or gut epithelium. This is why dermoid cysts present most commonly in childhood, near the lateral eyebrow, the midline forehead, the scalp, the nasal bridge, or other places where the face and skull bones meet during embryologic life.
The imaging that matters
Two imaging clues distinguish dermoid cysts from epidermoid cysts. First, on CT, dermoid cysts are radiolucent — average density around −68 Hounsfield units (the density of fat) because the cyst is filled with sebaceous gland secretions. Epidermoid cysts, filled with keratin, average +19 HU (Yun et al., 2024). Second, bony remodeling: because dermoid cysts grow slowly over years and sit at bony fusion lines, they often cause focal bony notching, scalloping, or dumbbell-shaped configurations in adjacent bone — a feature uncommon with epidermoid cysts.
When deep extension is suspected — particularly with midline forehead, nasal, or scalp dermoid cysts — MRI is strongly preferred over CT. In a recent series, MRI sensitivity for intracranial extension was 100%, with specificity 95.7%, versus 72.7% and 96.5% for CT (Meira Pazelli et al., 2024). For any dermoid cyst sitting near the midline of the skull, MRI before surgery is not optional.
The lancing rule, in detail
I want to dwell on this because it is the most consequential teaching point in this entire article: dermoid cysts should never be lanced.
I have seen the consequences of incision and drainage of a dermoid cyst more than once in referral practice. The cyst returns. The skin scars. The local anatomy becomes distorted. Subsequent definitive excision — which is the only operation that should ever have been performed — is now technically harder than it would have been if the patient had been brought to the operating room the first time.
The published evidence consistently supports this position. Complete surgical excision of pediatric head and neck dermoid cysts at the Mayo Clinic produced 1 recurrence in 49 patients (2%) (Pryor et al., 2005). A series of 234 consecutive scalp dermoid and epidermoid cysts reported zero recurrences after surgical excision (Prior et al., 2018). A single-center experience of 128 calvarial dermoid and epidermoid cysts confirmed that gross total resection is curative (Engler et al., 2016). A series of 115 periorbital dermoid cysts: 2.6% recurrence, with intraoperative rupture occurring in 7.8% of cases without necessarily increasing recurrence risk if meticulous removal of all cyst contents and wall was achieved (Montolío-Marzo et al., 2020; Lenci et al., 2017). A series of 55 midline frontonasal dermoids: no recurrences in the open surgical group (Moses et al., 2015).
By contrast, incision and drainage of a related congenital cystic lesion — the infected congenital preauricular cyst — produced a recurrence rate of 18.5%, compared with 3.3% for patients managed with antibiotics or fine-needle aspiration prior to definitive excision (absolute difference 15.2%; 95% CI, −1.7% to 33.6%) (Rataiczak et al., 2017). The 95% confidence interval crosses zero, so this 5.6-fold difference did not reach statistical significance in this small series — a limitation the authors themselves noted. The magnitude of the trend, however, combined with the biologic principle that leaving cyst wall behind regenerates the cyst, is what makes the clinical recommendation so consistent across the literature.
Beyond recurrence, incision and drainage of dermoid cysts is associated with persistent or recurrent infection, chronic drainage, fistula formation, and scarring that distorts local anatomy and complicates subsequent definitive excision (Lane et al., 1987). Early excision is advocated to prevent complications of cyst growth, including bone erosion and — in rare cases involving midline, nasal, or forehead lesions — intracranial extension (Prior et al., 2018; Moses et al., 2015; Meira Pazelli et al., 2024).
If a doctor — primary care, urgent care, emergency department — has offered to "lance" or "drain" what they think is a cyst on your child's forehead, nose, midline scalp, or near the eyebrow, please pause. Ask for a referral to a dermatologic surgeon, pediatric ophthalmologist (especially for periorbital lesions), or pediatric ENT for definitive evaluation first. A dermoid cyst that has been lanced is a much harder problem to fix than a dermoid cyst that has been left alone until the right operation can be planned. For midline lesions, request an MRI before any procedure.
What are the rarer cysts dermatologists encounter, and what do they signal?
A small subset of patients present with cysts that signal a syndromic disorder or an unusual biology, and these deserve recognition because the diagnosis on the skin can change a patient's entire workup.
Eruptive vellus hair cysts present as multiple small, dome-shaped papules on the chest or limbs in young adults. Histologically they are lined by squamous epithelium and contain small vellus hair shafts — the fine, pale hairs that cover most of the body's surface. The keratin profile is K17 positive, K10 negative — the mirror image of an epidermoid cyst (Tomková et al., 1997). Hybrid cysts that show features of both eruptive vellus hair cysts and steatocystoma multiplex are not unusual and reflect the close embryologic relationship of these two entities (Ahn et al., 1996).
Hybrid cysts and Goltz-Gorlin syndrome. A hybrid cyst shows features of more than one cyst type within a single lesion — alternating zones of trichilemmal and epidermoid keratinization, or pockets of vellus hair within a steatocystoma. Hybrid cysts can be sporadic, but they are also a recognized clue to Goltz-Gorlin syndrome (focal dermal hypoplasia) — a rare X-linked dominant disorder caused by mutations in the PORCN gene. (Worth pausing on the nomenclature: Goltz-Gorlin syndrome is not the same entity as Gorlin syndrome — also called the basal cell nevus syndrome — which is autosomal dominant, caused by PTCH1 mutations, and produces multiple basal cell carcinomas, jaw cysts, and palmar pits. The eponyms are similar enough to cause real bedside confusion. They are two completely different diseases that happen to share the surname.) In the Goltz-Gorlin context, hybrid cysts show exclusive K19 positivity and continuous BCL-2 staining — an immunohistochemical pattern that helps distinguish them from non-syndromic hybrid cysts (Tirado et al., 2014).
Cutaneous ciliated cysts are lined by ciliated columnar epithelium and most often appear on the lower extremities of young women. Immunohistochemistry helps separate them from non-Müllerian mimics: they often show estrogen and progesterone receptor positivity (Yalçın et al., 2024).
Eruptive multifocal cutaneous mucinous cysts present as multiloculated cystic structures lined by mucinous epithelium, with the diagnostic concern that on superficial examination, the histology can mimic metastatic mucinous carcinoma from the colon or breast. The distinction matters: a benign cutaneous cyst is observation or simple excision; a mucinous metastasis is a systemic cancer workup (Sebaratnam et al., 2018).
Cutaneous metaplastic synovial cysts arise at sites of previous trauma or surgery and are lined by tissue that resembles synovium — the membrane that lines true joints. They form in soft tissue scars, often with a characteristic "bag of worms" clinical appearance (Lin & Tsai, 2003).
How does a dermatopathologist tell all these cysts apart?
When a cyst lands on the pathologist's bench, the diagnostic logic runs through three layers in sequence. Each layer is fast, cheap, and additive.
Layer 1 — Clinical information. The most underrated diagnostic tool is the clinical history that accompanies the specimen. Where is the cyst? How long has it been there? Is the patient a child or an adult? Was there a central punctum? Are there multiple cysts? Does the family have anything similar? Three or four sentences of clinical context dramatically narrows the differential before a single slide is cut.
Layer 2 — Hematoxylin and eosin morphology. Then the routine stain. The pathologist examines the wall of the cyst and the contents, in that order. The wall tells us about the embryologic origin:
| Cyst Type | Wall Features |
|---|---|
| Epidermoid cyst | Stratified squamous epithelium with a granular layer; laminated keratin contents |
| Pilar cyst | Stratified squamous epithelium without a granular layer; compact, eosinophilic ("trichilemmal") keratin |
| Steatocystoma multiplex | Stratified squamous wall with sebaceous glands embedded in the wall; sebum contents |
| Dermoid cyst | Stratified squamous wall plus skin adnexal structures — sebaceous glands, hair follicles, sometimes respiratory or gut epithelium |
| Eruptive vellus hair cyst | Squamous wall containing small vellus hair shafts in the lumen |
| Proliferating trichilemmal tumor | Aggressive trichilemmal proliferation, atypia, occasional mitoses; can mimic squamous cell carcinoma |
| Hybrid cyst | Features of more than one cyst type within the same lesion |
Layer 3 — Immunohistochemistry: the K10/K17 workhorse. When morphology is ambiguous, the K10/K17 panel decisively resolves most cases (Tomková et al., 1997):
| Cyst | K10 | K17 |
|---|---|---|
| Epidermoid cyst | Positive | Negative |
| Eruptive vellus hair cyst | Negative | Positive |
| Steatocystoma multiplex | Positive | Positive |
| Pilar / trichilemmal cyst | Positive | Positive |
In the Goltz-Gorlin context, an additional K19 and BCL-2 panel can identify syndromic hybrid cysts (Tirado et al., 2014). For PTT, the molecular signature — 15q gain, 6q and 6p22.2 loss — distinguishes it from cutaneous squamous cell carcinoma when histology is ambiguous (Fischer et al., 2023). This is what evidence-based dermatopathology looks like in 2026: a stained slide, a smart panel, and — when needed — a chromosomal map.
Why does every cyst that comes out need to go to pathology?
This is the single most important slide in any patient counseling conversation I have about cyst excision, and it is the reason every excised cystic lesion should go to pathology, no exceptions.
In a clinicopathologic analysis of 2,438 cases by Kamyab and colleagues, nearly 20% of clinical diagnoses were discordant with histopathology, and 45 cases of malignancy had been initially presumed benign — with basal cell carcinoma accounting for 48.9% of these missed malignancies (Kamyab et al., 2020). A basal cell carcinoma can look exactly like a cyst on the surface. A squamous cell carcinoma can look like an inflamed cyst. A cutaneous lymphoma or even an infiltrating breast cancer metastasis can mimic recurrent hidradenitis or an inflamed cyst (Caputo et al., 2024).
This is not a hypothetical risk. The diagnostic accuracy data are sobering: dermatologists correctly diagnose neoplastic and cystic skin lesions 75% of the time, non-dermatology specialists 40%, and family practitioners 26% (Sellheyer & Bergfeld, 2005) — a near-tripling of accuracy from family practice to dermatology. These numbers explain why the rule for cyst excision is non-negotiable. Whatever comes out of the skin, into the formalin pot, and onto the slide — submit it. Even when you are 95% sure it is a routine cyst, the 5% is what protects the patient.
Dermoscopy is a useful adjunct but is not infallible. False-negative diagnoses can result in delayed recognition of melanoma, squamous cell carcinoma, or basal cell carcinoma, particularly in well-differentiated or amelanotic variants (Papageorgiou et al., 2018). The single, durable lesson: the diagnosis lives in the pathology lab, not in the clinic. Trust the slide.
One in five lesions clinically called a "cyst" is something else on histology. Nearly half of the missed cancers are basal cell carcinoma. The single rule that protects every patient is this: every excised cystic lesion gets sent for histologic examination. There is no exception, no shortcut, no reasonable cost-saving argument. The pathology report is the safety net.
Can a cyst actually turn into cancer?
The question every patient asks at the end of a cyst conversation: Can a cyst become cancer?
For practical purposes, the answer is no — but with the precision of a careful clinician's caveat. Squamous cell carcinoma arising from within an epidermoid cyst has been documented in the literature, but it is exceptionally rare. In the most recent case series, Kim and colleagues described 9 patients spanning multiple decades, with an average latency of 15.4 years from cyst recognition to malignant transformation (Kim et al., 2024). Strikingly, four of the nine patients had underlying chronic kidney disease or active cancer — pointing strongly to immune dysregulation as a driver of the transformation rather than the cyst itself being a precursor lesion in a healthy host.
In other words: a cyst in an otherwise healthy person almost certainly will not become cancer. A long-standing cyst in an immunosuppressed patient — a transplant recipient, a patient on chronic immunosuppressive therapy, a patient with active hematologic malignancy — deserves a closer look and a lower threshold for excision and biopsy.
The other cyst with a defined malignant potential is the proliferating trichilemmal tumor, covered earlier. Its malignant transformation rate is low but real, and it accounts for less than 0.1% of all cutaneous malignancies (Satyaprakash et al., 2007; Lee et al., 2023). Every other cyst on this list — pilar cysts (excluding PTT), steatocystoma multiplex, dermoid cysts, eruptive vellus hair cysts, hybrid cysts, ciliated cysts, mucinous cysts, synovial cysts — carries an essentially zero risk of malignant transformation. The cyst itself is biologically benign. The diagnostic question that matters in everyday practice is not whether the cyst will become cancer — it is whether the lesion that appears to be a cyst is actually a cyst at all.
What is the right treatment for each kind of cyst?
Treatment converges on a single biological principle: if the cyst wall is not removed, the cyst will come back. Every effective treatment in cyst surgery is, fundamentally, a wall-removal technique. Every failure is a wall-retention failure. With that principle in mind, here is the evidence base for each major cyst.
Epidermoid cysts
The American Academy of Family Physicians recommends complete surgical excision including the cyst wall, with recurrence rates approaching zero in large case series (Shen-Wagner et al., 2024; Achar et al., 2022; Prior et al., 2018). Minimally invasive alternatives include the minimal excision technique — a 2–3 mm incision, expression of the contents, then extraction of the cyst wall through the small opening, often without sutures (Zuber, 2002); punch excision for body cysts under about 1 cm; and the rectangular lid excision, which produces superior cosmetic outcomes compared with traditional elliptical excision, with no increase in complications (Kwon et al., 2019). Energy-based approaches have gained ground for facial or cosmetically sensitive cysts: erbium:YAG laser fenestration with no visible scar and high patient satisfaction (Feng & Ma, 2015), and plasma exeresis with scar 3 mm or less and no observed recurrences in published short-term follow-up (Rossi et al., 2018).
The single most important practical rule: never operate on an actively inflamed epidermoid cyst. Inflamed cysts are technically difficult, the wall is friable and tears, and incomplete removal is much more likely. The right move is intralesional corticosteroid injection to quiet the inflammation, then return for interval definitive excision two to four weeks later, with a vastly improved chance of complete wall removal (Shen-Wagner et al., 2024; Zuber, 2002).
Pilar cysts
Complete surgical excision is curative, with recurrence below 5% when the wall is entirely removed (Shen-Wagner et al., 2024; Zhu et al., 2023; Wang et al., 1992). The punch incision technique offers a minimally invasive alternative, with a recurrence rate of 3.6% by chart review and 8.3% by patient survey — most recurrences within the first year (Mehrabi et al., 2002). For patients with multiple or recurrent pilar cysts (often the familial PLCD1-driven phenotype), comprehensive surgical planning that addresses all clinically apparent lesions in a single staged operation produces better cosmetic outcomes than a piecemeal approach (Ibrahim et al., 2012).
Proliferating trichilemmal tumors
Wide local excision with clear histologic margins and long-term follow-up. Adjuvant radiotherapy or chemotherapy is reserved for invasive or metastatic disease (Satyaprakash et al., 2007; Sethi & Singh, 2002; Lee et al., 2023).
Steatocystoma multiplex
Procedural removal of the cyst wall is the only durable approach. Modified surgical extraction through a small puncture, with extraction of the wall through the opening, produced no recurrences at 14 months in published series (Kaya et al., 2001). CO₂ laser perforation and extirpation is increasingly favored, particularly for facial cosmesis (Bakkour & Madan, 2014; Rossi et al., 2003). Oral isotretinoin offers limited and often temporary benefit (Georgakopoulos et al., 2018).
Dermoid cysts
Complete surgical excision — never lancing, never incision and drainage — with imaging (MRI for midline lesions) preoperatively to evaluate for deep extension (Pryor et al., 2005; Prior et al., 2018; Engler et al., 2016; Montolío-Marzo et al., 2020; Moses et al., 2015; Meira Pazelli et al., 2024).
Eruptive vellus hair cysts
Most are asymptomatic and require no treatment. When symptomatic or cosmetically bothersome, excision or CO₂ laser ablation is reasonable.
Comparison table: treatment, recurrence, malignant potential
| Cyst Type | Genetic / Histologic Anchor | First-Line Treatment | Recurrence After Complete Excision | Malignant Potential |
|---|---|---|---|---|
| Epidermoid cyst | Sporadic; APC in Gardner syndrome; K10+ only | Complete surgical excision; intralesional steroid if inflamed | Near 0% | Exceptionally rare SCC (~15-year latency; predominantly in immunosuppressed patients) |
| Pilar (trichilemmal) cyst | PLCD1 two-hit mechanism in familial cases; K10+/K17+; no granular layer | Complete surgical excision or punch technique | Below 5% | Exceptionally rare except for PTT subset |
| Proliferating trichilemmal tumor | 15q gain; 6q and 6p22.2 loss | Wide local excision with clear margins | Higher if margins are incomplete | Low but real (under 0.1% of skin cancers); rare metastatic potential |
| Steatocystoma multiplex | KRT17; K10+/K17+; sebaceous glands in wall | Wall extraction via surgical puncture or CO₂ laser | Low; condition is chronic and new lesions appear | None |
| Dermoid cyst | Embryologic ectodermal sequestration; no heritable gene | Complete surgical excision; MRI for midline lesions | Below 3% | Exceptionally rare |
| Eruptive vellus hair cyst | K17+ only; vellus hairs in lumen | Excision if symptomatic | Very low | None |
| Hybrid cyst (syndromic in Goltz-Gorlin) | K19+, continuous BCL-2 in syndromic cases | Excision; genetic workup if syndromic features present | Low | None |
The phrase "sebaceous cyst" is one of the most persistent misnomers in medicine. True sebaceous cysts — meaning cysts whose wall contains sebaceous glands and whose lumen is filled with sebum — are steatocystomas, not the everyday firm bumps that patients call "sebaceous cysts." Those everyday bumps are epidermoid cysts, which contain compact keratin, not sebum, and have no sebaceous glands in the wall. The distinction is more than vocabulary — it changes both the differential diagnosis and the workup, because steatocystoma multiplex is a heritable condition driven by KRT17, while epidermoid cysts are almost always sporadic and isolated.
How should patients and clinicians make decisions about cyst treatment?
The conversation I have with patients about cysts has three parts, in this order: what we know, what we are going to do, and what we are going to watch for.
What we know. Most cysts are benign. The shape and feel of the lump under the skin is usually enough to tell us roughly what kind of cyst it is. If we operate, we send everything to the pathology lab — every time — because one in five "cysts" turns out to be something else, and we never want to be wrong about that.
What we are going to do. For epidermoid and pilar cysts, complete surgical excision removes the wall and prevents recurrence. For inflamed cysts, we calm the inflammation first with an injection and bring you back when the tissue is cooperating. For dermoid cysts in children — especially midline ones — we image first and operate properly. We never lance them, because lancing makes everything worse. For steatocystoma multiplex, we work on the cysts that are bothering you most, knowing new ones may appear over time.
What we are going to watch for. Multiple cysts in unusual places, or in young patients, or with a family history of cysts or colon cancer — those patterns deserve genetic evaluation. Rapid growth, ulceration, or sudden change in feel of a long-standing scalp cyst deserves urgent re-evaluation. And anyone who is immunosuppressed needs a lower threshold for excision and biopsy because the rare risk of squamous cell carcinoma in long-standing cysts concentrates in that population.
The 2016 British Journal of Dermatology shared-decision-making framework — combining patient values with clinical evidence under the guiding principle of patient autonomy — is the right approach to cyst care (Tan et al., 2016). Patients with lesions on the head or neck place particularly high value on cosmesis, and minimally invasive techniques exist for almost every cyst type that bothers a patient cosmetically (Martin et al., 2016; Backman et al., 2025). In patients with darker skin, treatment with cryotherapy or laser therapy should include explicit discussion of post-inflammatory hyperpigmentation and hypopigmentation risk (Shen-Wagner et al., 2024).
Test Your Cutaneous Cyst Knowledge
4 game modes to test what you've learned. Pick your style.
Choose your mode
Take your time. Get detailed explanations after each question.
15-second timer. Score points for speed. Build streaks for multipliers.
Pick your category. Pick your value. How much do you know?
Progressive difficulty. 3 lifelines. How far can you go?
Frequently Asked Questions
1. Is this lump on my body a cyst, and is it cancer?
Almost certainly a cyst, and almost certainly not cancer. The most common skin bumps that patients call "cysts" are epidermoid and pilar cysts, both of which are biologically benign. The exception worth knowing is that nearly 20% of lesions clinically diagnosed as cysts turn out to be something else on biopsy — most commonly basal cell carcinoma — which is why every cyst that gets surgically removed should be sent to the pathology lab for confirmation (Kamyab et al., 2020). The pathology report is the safety net.
2. Why can't I just have it drained?
Because draining a cyst does not remove the cyst wall — and the wall is what produces the cyst in the first place. If we drain without removing the wall, the keratin or sebum that gets evacuated is regenerated by the remaining epithelium, and the cyst returns. Effective treatment for any cyst requires wall removal. Draining alone is a temporary fix that almost guarantees recurrence.
3. Are sebaceous cysts a real thing?
True sebaceous cysts exist, but they are not what most patients mean when they use the term. Most people who say "sebaceous cyst" are describing an epidermoid cyst, which contains keratin rather than sebum and has no sebaceous glands in the wall. True sebaceous cysts are part of steatocystoma multiplex, a heritable condition driven by KRT17 mutations. The distinction is medically meaningful — the workup and treatment differ.
4. My doctor said my cyst is inflamed and wants me to come back in a few weeks. Why?
Because operating on an actively inflamed cyst is technically much harder, and the chance of leaving cyst wall behind — which guarantees recurrence — is much higher. The right sequence is an intralesional corticosteroid injection to calm the inflammation, then definitive excision two to four weeks later when the tissue planes are clean and the wall can be removed completely (Shen-Wagner et al., 2024; Zuber, 2002).
5. My child has a small lump on the side of the eyebrow. The pediatrician wants to drain it. Is that okay?
Please request a referral to a dermatologic surgeon, pediatric ophthalmologist (especially for periorbital lesions), or pediatric ENT before any procedure. A bump at the lateral eyebrow, midline forehead, nasal bridge, or scalp in a child is most likely a dermoid cyst — a developmental cyst that should never be lanced. Lancing a dermoid cyst makes the eventual definitive excision technically much more difficult. For midline lesions, MRI imaging is recommended before any operation to evaluate for deep extension (Meira Pazelli et al., 2024).
6. My family has a lot of pilar cysts on the scalp. Is this hereditary?
It can be — but the mechanism is more interesting than "dominant inheritance." Familial pilar cyst disease is now known to involve a monoallelic two-hit mechanism in the PLCD1 gene: family members carry a germline predisposing variant, but cyst formation in any individual hair follicle also requires a second somatic mutation on the same allele (Shimomura et al., 2019; Hörer et al., 2019). The clinical pattern looks dominant, but the molecular logic is closer to a tumor-suppressor model. A conversation with a genetic counselor is reasonable for families with multiple pilar cysts across generations.
7. My dermatologist mentioned that my multiple cysts might mean Gardner syndrome. Should I be worried?
Multiple epidermoid cysts — particularly on the extremities or in unusual locations — combined with a family history of cysts, bony osteomas (especially of the jaw), or colorectal cancer should trigger evaluation for Gardner syndrome, which is caused by mutations in the APC gene. The skin findings can predate colorectal polyposis by decades, so the early recognition matters enormously: appropriate surveillance can dramatically change the outcome (Shen-Wagner et al., 2024; Achar et al., 2022). Take the referral to gastroenterology and genetics seriously.
8. What is the difference between a regular cyst on my scalp and a "proliferating trichilemmal tumor"?
A regular pilar cyst is biologically inert — it sits there, sometimes for decades. A proliferating trichilemmal tumor (PTT) arises from the same tissue but shows aggressive epithelial proliferation, sometimes with malignant transformation. Clinically, the PTT often presents as a long-standing scalp cyst that has recently begun to grow rapidly, change in feel, or ulcerate. Molecularly, PTT carries a distinctive chromosomal pattern — gain of 15q and losses of 6q and 6p22.2 — that differs from cutaneous squamous cell carcinoma (Fischer et al., 2023). Any rapidly changing scalp lump deserves urgent evaluation and excision with pathology.
9. Can a cyst turn into cancer?
Almost never. Squamous cell carcinoma arising from an epidermoid cyst has been documented but is exceptionally rare, with an average latency of more than 15 years and a strong association with immunosuppression — particularly chronic kidney disease, organ transplantation, and active cancer (Kim et al., 2024). For an otherwise healthy patient with a long-standing cyst, the lifetime risk of malignant transformation is negligible. For an immunosuppressed patient with a long-standing cyst, the threshold for excision and biopsy should be lower.
10. What is the K10/K17 stain my pathology report mentioned?
K10 and K17 are keratin proteins expressed at different stages of skin and follicle development, and the combination of which ones a cyst expresses helps identify the cyst type. Epidermoid cysts express K10 only. Eruptive vellus hair cysts express K17 only. Steatocystoma multiplex and pilar cysts express both K10 and K17. This single immunohistochemical panel can distinguish these otherwise visually similar lesions and is a routine adjunct when the morphology is ambiguous (Tomková et al., 1997).
References
Kamyab K, Kianfar N, Dasdar S, Salehpour Z, Nasimi M. Cutaneous cysts: a clinicopathologic analysis of 2,438 cases. Int J Dermatol. 2020;59(4):457-462. PMID: 32034771
Al-Khateeb TH, Al-Masri NM, Al-Zoubi F. Cutaneous cysts of the head and neck. J Oral Maxillofac Surg. 2009;67(1):52-57. PMID: 19070748
Shen-Wagner J, Amidon J, Carek S. Diagnosing common benign skin tumors. Am Fam Physician. 2024;110(4):353-361. PMID: 39418568
Achar S, Yamanaka J, Oberstar J. Soft tissue masses: evaluation and treatment. Am Fam Physician. 2022;105(6):602-612. PMID: 35704829
Shimomura Y, O'Shaughnessy R, Rajan N. PLCD1 and pilar cysts. J Invest Dermatol. 2019;139(10):2075-2077. PMID: 31543210
Hörer S, Marrakchi S, Radner FPW, et al. A monoallelic two-hit mechanism in PLCD1 explains the genetic pathogenesis of hereditary trichilemmal cyst formation. J Invest Dermatol. 2019;139(10):2154-2163.e5. PMID: 31082376
Fischer GM, Lindeman NI, Ligon AH, Russell-Goldman E. Proliferating pilar tumors are characterized by recurrent 15q, 6q, and 6p22.2 alterations. Am J Dermatopathol. 2023;45(4):217-226. PMID: 36346171
Tomková H, Fujimoto W, Arata J. Expression of keratins (K10 and K17) in steatocystoma multiplex, eruptive vellus hair cysts, and epidermoid and trichilemmal cysts. Am J Dermatopathol. 1997;19(3):250-253. PMID: 9185910
Broekaert D, Goeman L, Ramaekers FC, et al. An investigation of cytokeratin expression in skin epithelial cysts and some uncommon types of cystic tumours using chain-specific antibodies. Arch Dermatol Res. 1990;282(6):383-391. PMID: 1701984
Ohnishi T, Watanabe S. Immunohistochemical observation of cytokeratins in keratinous cysts including plantar epidermoid cyst. J Cutan Pathol. 1999;26(9):424-429. PMID: 10563497
Bansal R, Honavar SG, Talloju SS, Mulay K. Orbital dermoid cyst. Indian J Ophthalmol. 2022;70(2):709. PMID: 35086291
Santos HB, Rolim LS, Barros CC, et al. Dermoid and epidermoid cysts of the oral cavity: a 48-year retrospective study with focus on clinical and morphological features and review of main topics. Med Oral Patol Oral Cir Bucal. 2020;25(3):e364-e369. PMID: 32134895
Whittle C, Silva-Hirschberg C, Loyola K, Fajre X, Andrews A. Ultrasonographic spectrum of cutaneous cysts with stratified squamous epithelium in pediatric dermatology: pictorial essay. J Ultrasound Med. 2023;42(4):923-930. PMID: 35792004
Yun HJ, Kim JH, Woo KI, Kim YD. Correlation between radiologic and histopathologic features of orbital epidermoid and dermoid cysts. Ophthalmic Plast Reconstr Surg. 2024;40(4):411-415. PMID: 38285927
Juan David DO, María de Los Ángeles VA, Claudia Ileana SC, María Elisa VM. Proliferating pilar tumors in the scalp over a period of 23 years in a general hospital in Mexico City. Dermatol Surg. 2023;49(8):759-761. PMID: 37399135
Ahn SK, Chung J, Lee WS, Lee SH, Choi EH. Hybrid cysts showing alternate combination of eruptive vellus hair cyst, steatocystoma multiplex, and epidermoid cyst. Am J Dermatopathol. 1996;18(6):645-649. PMID: 8989942
Yalçın AC, Yalçın N, Çakmak Hİ, Bedir R. Cutaneous ciliated cysts: 2 case reports and review of literature. Am J Dermatopathol. 2024;46(11):774-780. PMID: 38941541
Sebaratnam DF, Agar N, Cooper W, Jackett L. Eruptive multifocal cutaneous mucinous cysts. Am J Dermatopathol. 2018;40(1):e12-e14. PMID: 28700376
Lin YC, Tsai TF. Cutaneous metaplastic synovial cyst: unusual presentation with "a bag of worms." Dermatol Surg. 2003;29(2):198-200. PMID: 12562356
Tirado M, Ständer S, Metze D. Histologic and immunohistochemical characteristics of cutaneous cysts in Goltz-Gorlin syndrome. Am J Dermatopathol. 2014;36(11):892-898. PMID: 24698937
Pryor SG, Lewis JE, Weaver AL, Orvidas LJ. Pediatric dermoid cysts of the head and neck. Otolaryngol Head Neck Surg. 2005;132(6):938-942. PMID: 15944568
Prior A, Anania P, Pacetti M, et al. Dermoid and epidermoid cysts of scalp: case series of 234 consecutive patients. World Neurosurg. 2018;120:119-124. PMID: 30189303
Engler J, Bassani L, Ma T, et al. Open and endoscopic excision of calvarial dermoid and epidermoid cysts: a single center experience on 128 consecutive cases. Childs Nerv Syst. 2016;32(12):2351-2356. PMID: 27550433
Montolío-Marzo S, González-Valdivia H, Casas-Gimeno E, Sebastian-Chapman L, Prat-Bartomeu J. Dermoid cyst: outcome analysis in a pediatric referral hospital. Ophthalmic Plast Reconstr Surg. 2020;36(5):478-480. PMID: 32205776
Lenci LT, Shams P, Shriver EM, Allen RC. Dermoid cysts: clinical predictors of complex lesions and surgical complications. J AAPOS. 2017;21(1):44-47. PMID: 28089745
Moses MA, Green BC, Cugno S, et al. The management of midline frontonasal dermoids: a review of 55 cases at a tertiary referral center and a protocol for treatment. Plast Reconstr Surg. 2015;135(1):187-196. PMID: 25285685
Rataiczak H, Lavin J, Levy M, et al. Association of recurrence of infected congenital preauricular cysts following incision and drainage vs fine-needle aspiration or antibiotic treatment. JAMA Otolaryngol Head Neck Surg. 2017;143(2):131-134. PMID: 28033441
Lane CM, Ehrlich WW, Wright JE. Orbital dermoid cyst. Eye (Lond). 1987;1(Pt 4):504-511. PMID: 3443205
Meira Pazelli A, Wang L, Gates-Tanzer L, et al. Imaging yield and surgical outcomes of nasal, medial brow, forehead, and scalp dermoid cysts. Cleft Palate Craniofac J. 2024. PMID: 39491820
Zuber TJ. Minimal excision technique for epidermoid (sebaceous) cysts. Am Fam Physician. 2002;65(7):1409-1412, 1417-1418, 1420. PMID: 11996426
Kwon SH, Kim M, Shin JW, Na JI, Huh CH. Comparison of surgical outcomes of rectangular lid excision versus elliptical excision for the treatment of epidermal cysts. Dermatol Surg. 2019;45(9):1141-1146. PMID: 30672859
Feng CJ, Ma H. Treatment of epidermal cysts with erbium:YAG laser fenestration. Ann Plast Surg. 2015;74 Suppl 2:S89-92. PMID: 25695444
Rossi E, Paganelli A, Mandel VD, Pellacani G. Plasma exeresis treatment for epidermoid cysts: a minimal scarring technique. Dermatol Surg. 2018;44(12):1509-1515. PMID: 30020099
Zhu Z, Yang X, Fu J, Zhang S, Chong Z. Scalp trichilemmal cyst: a case report. Medicine (Baltimore). 2023;102(28):e34213. PMID: 37443491
Wang MB, Abemayor E, Fu YS. Tricholemmal cysts of the head and neck. Am J Otolaryngol. 1992;13(5):289-294. PMID: 1285561
Mehrabi D, Leonhardt JM, Brodell RT. Removal of keratinous and pilar cysts with the punch incision technique. Dermatol Surg. 2002;28(8):673-677. PMID: 12174056
Ibrahim AE, Barikian A, Janom H, Kaddoura I. Numerous recurrent trichilemmal cysts of the scalp. J Craniofac Surg. 2012;23(2):e164-e168. PMID: 22446459
Satyaprakash AK, Sheehan DJ, Sangüeza OP. Proliferating trichilemmal tumors: a review of the literature. Dermatol Surg. 2007;33(9):1102-1108. PMID: 17760602
Sethi S, Singh UR. Proliferating trichilemmal cyst: report of two cases, one benign and the other malignant. J Dermatol. 2002;29(4):214-220. PMID: 12027086
Lee DY, Han KM, Yoon JS. A malignant proliferating trichilemmal cyst arising on the elbow of a man. Medicine (Baltimore). 2023;102(25):e34035. PMID: 37352060
Kaya TI, Ikizoglu G, Kokturk A, Tursen U. A simple surgical technique for the treatment of steatocystoma multiplex. Int J Dermatol. 2001;40(12):785-788. PMID: 11903679
Bakkour W, Madan V. Carbon dioxide laser perforation and extirpation of steatocystoma multiplex. Dermatol Surg. 2014;40(6):658-662. PMID: 24852470
Rossi R, Cappugi P, Battini M, Mavilia L, Campolmi P. CO2 laser therapy in a case of steatocystoma multiplex. Int J Dermatol. 2003;42(4):302-304. PMID: 12694500
Georgakopoulos JR, Ighani A, Yeung J. Numerous asymptomatic dermal cysts: diagnosis and treatment of steatocystoma multiplex. Can Fam Physician. 2018;64(12):892-899. PMID: 30541803
Kim JY, Min S, Park JK, Kim SW. Squamous cell carcinoma arising from epidermal cyst: a case series of 9 patients. Ann Plast Surg. 2024;92(5):575-579. PMID: 38669586
Sellheyer K, Bergfeld WF. A retrospective biopsy study of the clinical diagnostic accuracy of common skin diseases by different specialties compared with dermatology. J Am Acad Dermatol. 2005;52(5):823-830. PMID: 15858472
Papageorgiou V, Apalla Z, Sotiriou E, et al. The limitations of dermoscopy: false-positive and false-negative tumours. J Eur Acad Dermatol Venereol. 2018;32(6):879-888. PMID: 29314288
Caputo V, Citterio A, Rongioletti F. Uncommon neoplasms mistakenly diagnosed as hidradenitis suppurativa. Clin Dermatol. 2024;42(6):641-645. PMID: 39270809
Pérez-Muñoz N, Llamas-Velasco M, Castillo-Capponi G, et al. Dermatopathology of cutaneous cystic lesions: a practical review. Am J Dermatopathol. 2019;41(11):783-793. PMID: 31633550
Tan J, Linos E, Sendelweck MA, et al. Shared decision making and patient decision aids in dermatology. Br J Dermatol. 2016;175(5):1045-1048. PMID: 27790692
Martin I, Schaarschmidt ML, Glocker A, et al. Patient preferences for treatment of basal cell carcinoma: importance of cure and cosmetic outcome. Acta Derm Venereol. 2016;96(3):355-360. PMID: 26537095
Backman E, Heckemann B, Gillstedt M, Polesie S, Paoli J. Patient preferences and cosmetic outcomes following destructive treatments for non-facial basal cell carcinoma. Acta Derm Venereol. 2025;105:adv41325. PMID: 39936608
About This Site
Skin Trust is a free educational website created by Dr. Thomas L.H. Hocker, M.D., M.Phil. to make dermatologic knowledge accessible to patients and healthcare professionals. All content is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Skin Trust is Dr. Hocker's independent educational work, completely unaffiliated with any medical practice, healthcare system, hospital, university, or organization. Using this website does not create a doctor-patient relationship. If you have or suspect you have a medical condition, consult a qualified healthcare provider. Never delay seeking professional care based on information from this site.
